Pharma Update

Key late-stage pipeline assets with 1bn+ sales potential* Roche Oncology, Hematology tiragolumab NSCLC, HCC, ESCC, SCCHN giredestrant HR+ BC divarasib KRAS+ NSCLC, CRC inavolisib Pi3Km BC crovalimab PNH, aHUS, SCD, LN Tecentriq Adj. SCCHN/HCC, tira combo Columvi 2L DLBCL, 1L DLBCL Lunsumio 2L DLBCL, R/R FL, 1LFL 1bn+ sales potential 2bn+ sales potential Neuroscience, Cardiometabolic Elevidys DMD fenebrutinib RMS, PPMS anti-latent myostatin mAb SMA, FSHD zilebesiran hypertension Ocrevus SC, high dose Enspryng gMG, MOGAD, AIE, TED Immunology, Ophthalmology astegolimab COPD ASO Factor B IgAN, GA anti-IL-6 UME, DME Gazyva LN, SLE, MN Oncology/Hematology Neuroscience Ophthalmology Immunology CVM Trial populations listed in appendix table 8 late-stage NMEs with CHF>2 bn each in peak sales potential 4 late-stage NMEs with CHF >1bn each in peak sales potential 2 marketed products with LEs that could add CHF>2 bn each in peak sales potential 4 marketed products with LEs that could add CHF>1 bn each in peak sales potential *8 with 2bn+ opportunities; LE=line extensions 66 66

View entire presentation